Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg(−1) wk(−1) or to a control group receiving epoetin alfa at an initial dose of 150 U kg(−1) three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg(−1...

Description complète

Détails bibliographiques
Auteurs principaux: Glaspy, J A, Jadeja, J S, Justice, G, Kessler, J, Richards, D, Schwartzberg, L, Tchekmedyian, N S, Armstrong, S, O'Byrne, J, Rossi, G, Colowick, A B
Format: Texte
Langue:English
Publié: Nature Publishing Group 2002
Sujets:
Clinical
Accès en ligne:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364226/
https://www.ncbi.nlm.nih.gov/pubmed/12177793
http://dx.doi.org/10.1038/sj.bjc.6600465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364226/
https://www.ncbi.nlm.nih.gov/pubmed/12177793
http://dx.doi.org/10.1038/sj.bjc.6600465

Documents similaires